For UK healthcare professionals only
Media partner:
GPnotebook
This website includes promotional information and is intended for UK healthcare professionals only. This website has been funded by Exeltis UK. Prescribing information and adverse event reporting information can be found at the bottom of the page. The media partner for this activity is GPnotebook. GPnotebook has had no input into the content of this website.

Menopause

For your patient who wants a simple and convenient once-daily oral HRT option

With so many different hormone replacement therapy (HRT) preparations available, the choice can be confusing for patients – and complicated for clinicians to explain in a short consultation.

FEMOSTON® (estradiol/dydrogesterone) is a combined oral HRT for the relief of oestrogen deficiency symptoms, covering a wide range of doses from sequential to continuous preparations.1-4

Why FEMOSTON®?

Lower breast cancer and VTE risk compared to other synthetic progestogens

Dydrogesterone is associated with a lower breast cancer and VTE risk compared to other synthetic progestogens (norethisterone acetate [NETA], medroxyprogesterone acetate [MPA],[levo]norgesterol)5-9

Effective vasomotor symptom control

FEMOSTON®-conti has been shown to have effective vasomotor symptom control compared to placebo,3,4,10 and both FEMOSTON®-conti 0.5mg/2.5 mg and 1 mg/5 mg were well tolerated3,4

Improved bleeding profile compared to placebo

Percentage of women with amenorrhoea increased from 81.1% and 74.6% at 3 months to 91.4% and 88.2% in months 10–12 in women receiving FEMOSTON®-conti 0.5 mg/2.5 mg and 1 mg/5 mg, respectively, compared to placebo (81.5%) N=30510

Osteoporosis prevention

FEMOSTON®-conti 1 mg/5 mg, FEMOSTON® 1 mg/10 mg and 2 mg/10 mg film-coated tablets are also indicated for the prevention of osteoporosis in postmenopausal women1,2,4

Effective endometrial protection

FEMOSTON® has been shown to provide effective endometrial protection in non-hysterectomised women1-4 with an acceptable bleeding and tolerability profile11-13

Not associated with increased cardiovascular risk compared to other HRT*

FEMOSTON® is not associated with a higher risk of cardiovascular events than use of other HRT14

*Other HRT = oral conjugated equine oestrogen (CEE) + norgestrel, oral estradiol (valerate) + norethisterone (acetate), or oral CEE + medroxyprogesterone acetate (MPA).

Menopause resources

58:32

ON-DEMAND

Navigating oral HRT in modern menopause management

Dr Vikram Talaulikar explains the complexity of menopause management, outlining the advantages and disadvantages of oral HRT regimens and highlighting key recommendations from the NICE and British Menopause Society (BMS) guidelines.

Dr Vikram Talaulikar

BMS-accredited Menopause Specialist and Honorary Associate Professor in Women’s Health, University College London

LEAFLET

FEMOSTON®: Guide for healthcare professionals

A useful resource offering a quick, practical overview of the key benefits of FEMOSTON® for healthcare professionals.

PATIENT INFORMATION

FEMOSTON®-conti 0.5 mg/2.5 mg

Guide for your patients who have been prescribed FEMOSTON® -conti

PATIENT INFORMATION

FEMOSTON®-conti 1 mg/5 mg

Guide for your patients who have been prescribed FEMOSTON® -conti

PATIENT INFORMATION

FEMOSTON® 1 mg/10 mg & 2 mg/10 mg

Guide for your patients who have been
prescribed FEMOSTON®

Sign up to hear from Exeltis

All fields required

I consent to receive news and information about Exeltis UK’s brands and products. I understand my personal data becomes processed according the Exeltis UK privacy notice. View Privacy Policy I understand I can withdraw consent whensoever.
You can unsubscribe at any time by clicking the unsubscribe link in the footer of our emails.

FEMOSTON® is indicated for oestrogen deficiency symptoms in post menopausal women at least 6 months since last menses1-2 and FEMOSTON®-conti is indicated for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.3-4

BMS, British Menopause Society; HCP, healthcare professional; HRT, hormone replacement therapy; MPA, medroxyprogesterone acetate; NETA, norethisterone acetate; NICE, National Institute for Health and Care Excellence; VTE, venous thromboembolism.

References

  1. FEMOSTON® 1 mg/10 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/5523/smpc (Accessed September 2025).
  2. FEMOSTON® 2 mg/10 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3903/smpc (Accessed September 2025).
  3. FEMOSTON®-conti 0.5 mg/2.5 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2825/smpc (Accessed September 2025).
  4. FEMOSTON®-conti 1 mg/5 mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/1347/smpc (Accessed September 2025).
  5. Fournier A, et al. Breast Cancer Res Treat. 2008;107:103–111.
  6. Vinogradova Y, et al. BMJ. 2019; 364:k4810.
  7. Baber RJ, et al. Climacteric. 2016;19(2):109–150.
  8. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 2019; 394(10204):1159–1168.
  9. Vinogradova Y, et al. BMJ. 2020;371:m387.
  10. Stevenson JC, et al. Maturitas. 2010;67(3):227–232.
  11. Ferenczy A, et al. Climacteric. 2002;5(1): 26–35.
  12. Quereux C, et al. Maturitas. 2006;53(3):299–305.
  13. Bergeron C, et al. Maturitas. 2010;66(2): 201–205.
  14. Schneider CC, et al. Climacteric. 2009;12(5):445–453.

Prescribing and adverse event reporting information:

FEMOSTON® (estradiol/dydrogesterone)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to [email protected]

EXE-E/IPR-FEM-1875-v1 | September 2025

For UK healthcare professionals only
GPnotebook

This website includes promotional information and is intended for UK healthcare professionals only. This website has been funded by Exeltis UK

This site is intended for UK healthcare professionals only

To continue, please confirm that you are a UK healthcare professional by selecting one of the buttons below.

Yes, I am a UK healthcare professional
No, I am not a UK healthcare professional

You are leaving https://resources.gpnotebook.com

Text

Text

Close

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel